The Trump administration is closing in on a deal to allow Medicare coverage of weight loss drugs by Eli Lilly and Novo Nordisk in some cases, according to multiple reports.
Why it matters: A deal could significantly expand seniors' access to popular weight loss drugs while drastically decreasing the estimated cost of that coverage.